Effectiveness of Periocular Drug Injection in CATaract Surgery
Key facts
- Who runs it
- Luigi Rondas
- Where
- Austria, Germany, Netherlands, and Portugal10 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 628 people enrolled
- Started
- 13 Oct 2021
- Ended
- 13 Aug 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bromfenac
- Dexamethasone
- Triamcinolone Acetonide
- Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
- Record updated
- 4 November 2024
- Why it stopped
- Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- who are undergoing routine phacoemulsification (one eye per patient)
- who are 21 years or older
- who should be able to communicate properly and understand instructions
- willing and/or able to comply with the scheduled visits and other study procedures
Who cannot take part
- combined surgery (e.g. combined phacoemulsification and trabeculectomy)
- patients with an increased risk of developing cystoid macular edema (CME) in the study eye (e.g. diabetes mellitus, previous retinal venous occlusion, or a history of uveitis, macular edema, epiretinal membrane, or previous retinal surgery)
- patients who developed CME after cataract surgery in the contralateral eye
- patients using drugs that reduce or increase the risk of macular edema (e.g., periocular or intraocular corticosteroid, NSAID, or antivascular endothelial growth factor (VEGF) injection; topical corticosteroid or NSAID use; systemic corticosteroids (>= 20mg prednisolon), methotrexate, biologicals, or acetazolamide), or in the previous 4 months
- patients with a contraindication for any of the investigated drugs
- patients with permanent moderate visual impairment in the contralateral eye (decimal visual acuity less than 0.3)
- patients with a history of steroid induced IOP rise or glaucomatous visual field loss
- patients who have a history of hyperthyroidism
- patients who already participated with their contralateral eye
- patients with cystoid macular changes in the study eye at baseline
- patients with an increased risk of developing perioperative complications (e.g. Fuchs' endothelial dystrophy)
- patients who are cardiovascular unstable
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Cystoid macular edema (CME) is a major cause of suboptimal postoperative visual acuity after cataract surgery. Topical steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent CME. However, noncompliance with eye drops may compromise the effectiveness of treatment. Dropless periocular drug delivery during cataract surgery may improve the outcomes and cost-effectiveness of cataract surgery, and may alleviate the burden on homecare organizations.
The 4 groups in the trial
- topical bromfenac & dexamethasoneExisting treatment, for comparison
bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively \& dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week.
Treatment: Bromfenac and Dexamethasone
- subconjunctival triamcinolone acetonideExisting treatment, for comparison
one subconjunctival injection of 10 mg triamcinolone acetonide during cataract surgery (TA, Triesence/Vistrec) in the inferotemporal quadrant, 6mm from the limbus.
Treatment: Triamcinolone Acetonide
- intracameral ketorolacExisting treatment, for comparison
intracameral injection of ketorolac tromethamine solution during cataract surgery (Omidria). A 4ml vial of Omidria (ketorolac concentration 2.88mg/ml) is added to 500ml of the irrigation solution used during cataract surgery, resulting in a ketorolac concentration of 0.023mg/ml. At the end of the surgery, the anterior chamber will be filled with the ketorolac solution.
Treatment: Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
- subconjunctival triamcinolone acetonide & intracameral ketorolacExisting treatment, for comparison
one subconjunctival injection of 10 mg triamcinolone acetonide \& intracameral injection of ketorolac tromethamine solution (Omidria; 0.023mg/mL) during cataract surgery.
Treatment: Triamcinolone Acetonide and Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
- Record updated
- 4 November 2024